Compare PLAG & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAG | BOLT |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | 45 | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.4M | 7.3M |
| IPO Year | 2007 | 2021 |
| Metric | PLAG | BOLT |
|---|---|---|
| Price | $0.59 | $3.99 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | ★ 787.4K | 11.2K |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 32.56 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,040,616.00 | ★ $7,695,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $133.33 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 0.07 |
| 52 Week Low | $0.49 | $3.75 |
| 52 Week High | $4.49 | $7.20 |
| Indicator | PLAG | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 30.53 | 47.66 |
| Support Level | $0.49 | $3.87 |
| Resistance Level | $2.10 | $4.46 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 7.64 | 32.17 |
Planet Green Holdings Corp is a diversified technology and consumer products company with a presence in North America and China engaged in Chemical Products, Tea Products, and Online Advertising Services. The company operates in three segments namely to grow, produce, and distribute Cyan brick tea, black tea, and green tea in China; to research, develop, manufacture, and sell chemical products including formaldehyde, urea formaldehyde adhesive, methylal, ethanol fuel, fuel additives and clean fuel in China; and to develop and operate a demand-side platform which empowers buyers of advertising to manage and optimize their digital advertising across different real-time bidding networks in North America and China.
Bolt Biotherapeutics Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. The company is focused on the clinical development of BDC-4182, its claudin 18.2 ISAC. Its other pipeline programs include CEA ISAC program a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5, or CEA; PD-L1 ISAC utilizes a novel human anti-PD-L1 antibody conjugated to a next-generation TLR7/8 agonist payload via a non-cleavable linker; and BDC-3042, its dectin-2 agonist antibody program, developed to repolarize critical cells in the tumor microenvironment known as tumor associated macrophages. It operates in single segment.